Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Several other research firms have also recently weighed in on CNCE. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Monday, May 8th. ValuEngine upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. HC Wainwright began coverage on shares of Concert Pharmaceuticals in a research report on Monday, July 24th. They set a “buy” rating and a $20.00 price objective on the stock. Stifel Nicolaus restated a “buy” rating and set a $30.00 price objective (down previously from $31.00) on shares of Concert Pharmaceuticals in a research report on Monday, July 10th. Finally, Aegis restated a “buy” rating and set a $25.00 price objective on shares of Concert Pharmaceuticals in a research report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $25.17.

Concert Pharmaceuticals (NASDAQ:CNCE) traded down 0.63% during mid-day trading on Friday, hitting $14.11. 68,985 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $14.14 and its 200-day moving average price is $13.70. The stock’s market cap is $318.35 million. Concert Pharmaceuticals has a 12 month low of $7.11 and a 12 month high of $19.11.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/06/concert-pharmaceuticals-inc-cnce-rating-lowered-to-sell-at-bidaskclub.html.

A number of institutional investors have recently modified their holdings of CNCE. Driehaus Capital Management LLC acquired a new position in shares of Concert Pharmaceuticals during the first quarter worth approximately $7,353,000. Lyon Street Capital LLC acquired a new position in shares of Concert Pharmaceuticals during the first quarter worth approximately $1,467,000. Paulson & CO. Inc. acquired a new position in shares of Concert Pharmaceuticals during the first quarter worth approximately $1,198,000. KCG Holdings Inc. acquired a new position in shares of Concert Pharmaceuticals during the first quarter worth approximately $1,141,000. Finally, Prudential Financial Inc. boosted its position in shares of Concert Pharmaceuticals by 26.2% in the first quarter. Prudential Financial Inc. now owns 253,130 shares of the biotechnology company’s stock worth $4,319,000 after buying an additional 52,500 shares during the last quarter. Institutional investors own 62.80% of the company’s stock.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.